Outcomes of diabetics receiving bare-metal stents versus drug-eluting stents

Catheterization and Cardiovascular Interventions

Volumn 76, Issue 4, 2010, Pages 473-481

  Ramanath, Vijay S ^a   Brown, Jeremiah R ^a,b   Malenka, David J ^a   Devries, James T ^a   Sidhu, Mandeep S ^a   Robb, John F ^a   Jayne, John E ^a   Hettleman, Bruce D ^a   Friedman, Bruce J ^a   Niles II, Nathaniel W ^a   Kaplan, Aaron V ^a   Thompson, Craig A ^c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bare metal stent; diabetes mellitus; drug eluting stent; outcomes

Indexed keywords

ADULT; AGED; ARTICLE; BARE METAL STENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RECURRENT DISEASE; REVASCULARIZATION; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; NEW ENGLAND; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649425294     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22512     Document Type: Article

References (27)

1. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL,. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006; 151: 1260-1264.
2. Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R, Brooks MM, Bourassa MG, Shemin RJ, Rosen AD, et al. Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99: 633-640.
3. Flaherty JD, Davidson CJ,. Diabetes and coronary revascularization. JAMA 2005; 293: 1501-1508.
4. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS, Jr., Morris DC, King SB, III,. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979-989.
5. Ramanath VS, Eagle KA,. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007; 7: 95-116.
6. Ko DT, Chiu M, Austin PC, Bowen J, Cohen EA, Tu JV,. Safety and effectiveness of drug-eluting stents among diabetic patients: A propensity analysis. Am Heart J 2008; 156: 125-134.
7. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation 2005; 112: 2175-2183.
8. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW,. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28: 26-32.
9. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109: 2273-2278.
10. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L,. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: Results from the Massachusetts Data Analysis Center Registry. Circulation 2008; 118: 2277-2285, 7p following 2285.
11. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
12. Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM,. Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol 1985; 121: 754-766.
13. Schisterman EF, Whitcomb BW,. Use of the Social Security Administration Death Master File for ascertainment of mortality status. Popul Health Metr 2004; 2: 2.
14. Wentworth DN, Neaton JD, Rasmussen WL,. An Evaluation of the Social-Security-Administration Master Beneficiary Record File and the National-Death-Index in the Ascertainment of Vital Status. Am J Pub Health 1983; 73: 1270-1274.
15. Brown JR, Cochran RP, MacKenzie TA, Furnary AP, Kunzelman KS, Ross CS, Langner CW, Charlesworth DC, Leavitt BJ, Dacey LJ, et al. Long-term survival after cardiac surgery is predicted by estimated glomerular filtration rate. Ann Thorac Surg 2008; 86: 4-11.
16. Brown JR, Malenka DJ, DeVries JT, Robb JF, Jayne JE, Friedman BJ, Hettleman BD, Niles NW, Kaplan AV, Schoolwerth AC, et al. Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: Insights from the Dartmouth Dynamic Registry. Catheter Cardiovasc Interv 2008; 72: 347-354.
17. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
18. Doyle B, Rihal CS, O'Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, Bresnahan J, Holmes DR, Jr,. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007; 116: 2391-2398.
19. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C,. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954-959.
20. Anstrom KJ, Kong DF, Shaw LK, Califf RM, Kramer JM, Peterson ED, Rao SV, Matchar DB, Mark DB, Harrington RA, et al. Long-term clinical outcomes following coronary stenting. Arch Intern Med 2008; 168: 1647-1655.
21. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, Sangiorgio P, Tarantino F, Geraci G, Castriota F, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: Results from a real-world multicenter registry. Circulation 2008; 117: 923-930.
22. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW,. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
23. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, Sheiban I, Suttorp MJ, Vranckx P, Rademaker T, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol 2008; 52: 1957-1967.
24. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
25. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
26. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, SanMartin M, Gomez-Hospital JA, Banuelos C, Escaned J, Moreno R, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: Long-term results of the DIABETES trial. Eur Heart J 2007; 28: 1946-1952.
27. Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS,. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA 2008; 299: 2868-2876.